Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)
Clicks: 173
ID: 111252
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
173 views
51 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #358 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
After 48 weeks of immunonutrition in HIV-infected individuals starting antiretroviral therapy at advanced disease, most of the T-cell, inflammation, and bacteri
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (20 words).
Try re-searching for a better abstract.
| Reference Key |
sergio2019clinicaleffects
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Serrano-Villar, Sergio;de Lagarde, María;Vázquez-Castellanos, Jorge;Vallejo, Alejandro;Bernadino, José I;Madrid, Nadia;Matarranz, Mariano;Díaz-Santiago, Alberto;Gutiérrez, Carolina;Cabello, Alfonso;Villar-García, Judit;Blanco, José Ramón;Bisbal, Otilia;Sainz, Talía;Moya, Andrés;Moreno, Santiago;Gosalbes, María José;Estrada, Vicente; |
| Journal | clinical infectious diseases |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.